CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Part A: RPL554 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04091360
NCT04091360Phase 2Completed
CompareCT.gov

A Phase II, Randomised Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Pressurised Metered Dose Inhaler in Patients With COPD

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA·interventional·Posted Sep 16, 2019·Updated Sep 21, 2022

In Brief

A Phase 2 clinical trial evaluating Part A: RPL554, Placebos, and 1 other intervention for COPD. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by pressurized metered dose inhaler (pMDI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited Kingdom
CollaboratorsIQVIA Pty Ltd

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 16, 2019
Enrollment StartApr 29, 2019
Primary CompletionDec 10, 2020
Study CompletionJan 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.8 years ago

Interventions

Part A: RPL554drug

Single dose RPL554 via metered dose inhaler.

Placebosdrug

Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.

Part B: RPL554drug

Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.